Role
Chief Investigator
Description
We intend to develop an orally delivered peptide that can modulate the immune system and be developed as a therapeutic for inflammatory bowel disease. We have identified a peptide, derived from a hookworm protein, that alleviates the clinical symptoms of experimental colitis when orally administered to mice. The peptide has bioactivity with human cells ex vivo and displays desirable drug-like properties. The aim of this project is to acquire further data on the mechanism of action and formulation conditions to facilitate formal product development prior to licensing and clinical trials.
Date
01 Jan 2020 - 30 Jun 2022
Project Type
GRANT
Keywords
Inflammatory Bowel Disease;Peptide;therapeutic;Hookworm;Oral delivery
Funding Body
N/A
Amount
0
Project Team
Keith Dredge;Matthew Moyle;John Miles;Ashley Van Waardenberg;Norelle Daly;Paul Giacomin;Matt Field;Roland Ruscher